Century Therapeutics, Inc. — fact timeline

Century Therapeutics, Inc.: Increased authorized shares of common stock from 300,000,000 to 450,000,000 via a Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation (effective 2026-06-12).

“the stockholders of Century Therapeutics, Inc. (the “Company”) approved a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock, par value $0.0001 per share (“Common Stock”, and such amendment, the “Authorized Shares Amendment”). The Authorized Shares Amendment was previously approved by the Board, subject to stockholder approval. The Authorized Shares Amendment was filed with the Secretary of State of the State of Delaware on June 11, 2026. The Authorized Shares Amendment became effective on June 12, 2026.”

Century Therapeutics, Inc. shareholders approved Approval of an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 at the 2026-06-11 meeting.

“The adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 3 was approved, but such an adjournment was not necessary in light of the approval of Proposal 3 at the Annual Meeting. The adjournment was approved, as follows: For Against Abstentions Broker Non-Votes 117,181,181 18,419,826 88,087 0”

Century Therapeutics, Inc. shareholders approved Approval of an amendment to the Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 at the 2026-06-11 meeting.

“The amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 was approved, as follows: For Against Abstentions Broker Non-Votes 117,444,445 18,150,386 94,262 0”

Century Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2026-06-11 meeting.

“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 135,560,408 107,111 21,578 0”

Century Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-11 meeting.

“Each of Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A., were elected to the Company’s Board to serve as Class II directors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Alessandro Riva, M.D. 96,165,182 17,582,584 21,941,333 Han Lee, Ph.D., M.B.A. 113,675,805 71,961 21,941,333”

Century Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same.

“Century Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Century Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $109.2 million.

“first quarter of 2029. · Collaboration Revenue: Collaboration revenue generated through the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the same period in 2024. · Research and Development (R&D) Expenses: R&D expenses were $95.7 million for the”

Century Therapeutics, Inc. issued 92,030,595 shares of common stock of common stock to institutional accredited investors for $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock.

“On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen”

Century Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $135.0 million (effective 2026-01-07).

“On January 7, 2026, Century Therapeutics, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and/or, (ii) pre-funded warrants to purchase 25,360,704 shares of Common Stock (“Pre-Funded Warrants”) and (b) warrants to purchase 58,695,648 shares of Common Stock or Pre-Funded Warrants in lieu thereof (“Common Warrants”, together with the Pre-Funded Warrants, the “Warrants”) at a purchase price of $1.15 per share and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant and a purchase price of $1.1499 per Pre-Funded Warrant and accompanying Common Warrant to purchase 0.5 shares of Common Stock or Pre-Funded Warrant (the “Private Placemen”

Century Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse sto”

Century Therapeutics, Inc. announced a restructuring with charges of approximately $3.7 million (approximately 51%).

“On July 1, 2025, the Board of Directors (the “ Board ”) of Century Therapeutics, Inc. (the “ Company ”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential for transformational value. The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”). As part of the RIF, the Company estimates that it will incur charges of approximately $3.7 million for severance and other employee termination-related costs.”

Century Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 26, 2025, Century Therapeutics, Inc. (the “Company”) received a notification letter (the “Bid Price Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 31 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). The Bid Price Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares o”

Morgan Conn was appointed as Chief Financial Officer at Century Therapeutics, Inc..

“On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).”

Century Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.”

Century Therapeutics, Inc. completed an acquisition involving Clade Therapeutics, Inc. for approximately $35 million (closed 2024-04-11).

“the Merger and a wholly owned indirect subsidiary of the Company. Pursuant to the terms of the Merger Agreement, the aggregate upfront consideration was approximately $35 million, consisting of (i) approximately $15 million in cash and (ii) 4,535,333 shares of the Company’s common stock, par value $0.0001 per share (the “Merger Shares”). The cash portion”

Century Therapeutics, Inc. entered into Agreement and Plan of Merger with Clade Therapeutics, Inc. valued at aggregate upfront consideration was approximately $35 million (effective 2024-04-11).

“On April 11, 2024, the Company, Clarent Intermediate Sub, Inc. (“Intermediate Sub”), a wholly owned subsidiary of Company, and Clarent Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Intermediate Sub, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Clade Therapeutics, Inc. (“Clade”) and Fortis Advisors LLC, solely in its capacity as Securityholders’ Agent.”

Century Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds of approximately $60 million (effective 2024-04-11).

“On April 11, 2024, Century Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 15,873,011 shares of the Company’s common stock, par value $0.0001 per share (the “Private Placement Shares”), at a price of $3.78 per share (the “Private Placement”).”

Century Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.

“Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”

Douglas Carr was appointed as interim Principal Financial Officer at Century Therapeutics, Inc..

“Following the effectiveness of Dr. Diem’s resignation and until a new Chief Financial Officer is appointed, Douglas Carr, the Company’s Senior Vice President, Finance and Operations, will serve as interim Principal Financial Officer.”

Michael C. Diem resigned as Chief Financial Officer at Century Therapeutics, Inc..

“On January 15, 2024, Michael C. Diem, M.D. notified Century Therapeutics, Inc. (the “Company”) of his decision to resign as Chief Financial Officer of the Company, effective as of February 2, 2024.”

Gregory Russotti changed role as Chief Technology and Manufacturing Officer at Century Therapeutics, Inc..

“Dr. Russotti will serve as the Company’s Chief Technology and Manufacturing Officer.”

Brent Pfeiffenberger was appointed as member of the Board at Century Therapeutics, Inc..

“Dr. Pfeiffenberger was appointed to serve as a member of the Board”

Brent Pfeiffenberger was appointed as President and Chief Executive Officer at Century Therapeutics, Inc..

“appointed Brent Pfeiffenberger to serve as the Company’s President and Chief Executive Officer, effective December 4, 2023”

Century Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $0.1 million, net income $32.7 million. Guidance reaffirmed.

“(BMS) collaboration of $118.5 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option, and license agreement with BMS was $0.1 million for the three months ended September 30, 2023 compared to $2.2 million for the same period in 2022. Revenue recognized under the collaboration agreement fluctuates based on the”

Century Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $33.3 million for the three months ended June 30, 2023. Guidance reaffirmed.

“issued a press release announcing its financial results for the quarter ended June 30, 2023”

Century Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.

“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 55,396,113 5,068 2,839 -”

Century Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-27 meeting.

“Each of Cynthia Butitta, Timothy Walbert and Alessandro Riva, M.D. were elected to the Board to serve as Class II directors until the 2026 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Withheld Broker Non-Votes Cynthia Butitta 50,643,653 808, 082 3,952,285 Timothy Walbert 47,566,726 3,885,009 3,952,285 Alessandro Riva, M.D. 50,658,311 793,424 3,952,285”

Century Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.7 million. Guidance reaffirmed.

“of $122.1 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option and license agreement with Bristol-Myers Squibb was $1.7 million for the three months ended March 31, 2023, compared to $1.1 million for the same period in 2022. · Research and Development (R&D) expenses : R&D expenses were $24.9 million for”

Michael Diem was appointed as Chief Financial Officer at Century Therapeutics, Inc..

“On April 11, 2023, the Board promoted Dr. Michael Diem to Chief Financial Officer.”

Osvaldo Flores departed as President and Chief Executive Officer at Century Therapeutics, Inc..

“Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.”

Michael Diem changed role as Chief Financial Officer at Century Therapeutics, Inc..

“On April 11, 2023, the Board promoted Michael Diem to Chief Financial Officer.”

Gregory Russotti was appointed as Interim President and Chief Executive Officer at Century Therapeutics, Inc..

“On April 11, 2023, the Board appointed Gregory Russotti as Interim President and Chief Executive Officer.”

Osvaldo Flores departed as President and Chief Executive Officer at Century Therapeutics, Inc..

“Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of Century Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.”

Century Therapeutics, Inc. reported the full-year ended December 31, 2022 results: revenue $5.2 million, net income $130.9 million. Guidance reaffirmed.

“of $118.0 million), compared to net cash used in operations of $89.0 million for the twelve months ended December 31, 2021. · Collaboration Revenue: Collaboration revenue was $5.2 million for the twelve months ended December 31, 2022, generated through the Company’s collaboration, option and license agreement with BMS. · Research and Development (R&D) expenses :”

Century Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue Collaboration revenue was $2.2 million, net income Net loss was $30.7 million. Guidance lowered.

“of $118.5 million) compared to net cash used in operations of $64.7 million for the nine months ended September 30, 2021. ● Collaboration Revenue: Collaboration revenue was $2.2 million for the three months ended September 30, 2022, generated through the Company’s collaboration, option and license agreement with BMS. ● Research and Development (R&D) expenses”

Timothy P. Walbert was appointed as Director at Century Therapeutics, Inc..

“and (ii) Mr. Timothy P. Walbert to serve as a Class II director”

Daphne Quimi was appointed as Director at Century Therapeutics, Inc..

“the Board appointed (i) Ms. Daphne Quimi to serve as a Class I director of the Company”

Eli Casdin resigned as Director at Century Therapeutics, Inc..

“Eli Casdin tendered his resignation as a member of the board of directors (the “ Board ”) of Century Therapeutics, Inc.”